---
figid: PMC5031078__nihms393021f1
figlink: /pmc/articles/PMC5031078/figure/F1/
number: Figure 1
caption: Mutational activation of KRAS is found in >90% of PDA and contributes to
  tumor initiation and progression of the disease. PDA is almost universally fatal
  due to late-stage at diagnosis and intrinsic resistance to conventional chemotherapy
  and radiation. Data from Collisson and colleagues suggests that activation of BRAF
  (highlighted in red) is sufficient to recapitulate the tumor initiation and progression
  seen with activated KRAS in mouse and human PDA. These data imply that targeting
  RAF/MEK/ERK signaling downstream of KRAS may be of clinical utility in PDA. Treatment
  with MEK inhibitors is associated with a reciprocal increase in AKT activity and
  MEK inhibitor based combinatorial approaches will be needed to induce durable tumor
  regressions. Selective inhibitors of RAF (Vemurafinib, Dabrafenib) and MEK (Trametinib)
  kinases have recently been shown to prolong survival in patients with BRAFV600E
  mutant melanomas. Selective inhibitors of RAF induce a paradoxical activation of
  ERK signaling in KRAS mutant tumors whereas MEK inhibitors downregulate ERK pathway
  activity irrespective of tumor genotype.
pmcid: PMC5031078
papertitle: RAF/MEK dependence of KRAS mutant pancreatic ductal adenocarcinomas.
reftext: Aphrothiti J. Hanrahan, et al. Cancer Discov. 2012 Aug;2(8):666-669.
pmc_ranked_result_index: '68290'
pathway_score: 0.9528766
filename: nihms393021f1.jpg
figtitle: RAF/MEK dependence of KRAS mutant pancreatic ductal adenocarcinomas
year: '2012'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5031078__nihms393021f1.html
  '@type': Dataset
  description: Mutational activation of KRAS is found in >90% of PDA and contributes
    to tumor initiation and progression of the disease. PDA is almost universally
    fatal due to late-stage at diagnosis and intrinsic resistance to conventional
    chemotherapy and radiation. Data from Collisson and colleagues suggests that activation
    of BRAF (highlighted in red) is sufficient to recapitulate the tumor initiation
    and progression seen with activated KRAS in mouse and human PDA. These data imply
    that targeting RAF/MEK/ERK signaling downstream of KRAS may be of clinical utility
    in PDA. Treatment with MEK inhibitors is associated with a reciprocal increase
    in AKT activity and MEK inhibitor based combinatorial approaches will be needed
    to induce durable tumor regressions. Selective inhibitors of RAF (Vemurafinib,
    Dabrafenib) and MEK (Trametinib) kinases have recently been shown to prolong survival
    in patients with BRAFV600E mutant melanomas. Selective inhibitors of RAF induce
    a paradoxical activation of ERK signaling in KRAS mutant tumors whereas MEK inhibitors
    downregulate ERK pathway activity irrespective of tumor genotype.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MTOR
  - MAP2K2
  - RICTOR
  - MAP2K1
  - AKT3
  - PIK3R6
  - RPTOR
  - PIK3CA
  - KRAS
  - PIK3CG
  - PIK3R3
  - PIK3CB
  - PIK3CD
  - MAPK1
  - PDK1
  - AKT1
  - AKT2
  - TP53
  - NF1
  - PIK3R5
  - PIK3R4
  - MAPKAP1
  - RALGDS
  - RAF1
  - MLST8
  - IRS1
  - BRAF
  - PTEN
  - MAPK3
  - ARAF
  - PD0325901
  - AZD6244
  - BEZ235
  - RO4927350
  - Trametinib
  - Dabrafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
genes:
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: tp53
  symbol: TP53
  source: hgnc_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: NF-1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: RalGDS
  symbol: RALGDS
  source: hgnc_symbol
  hgnc_symbol: RALGDS
  entrez: '5900'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: IRS1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
chemicals:
- word: PD0325901
  source: MESH
  identifier: C506614
- word: AZD6244
  source: MESH
  identifier: C517975
- word: BEZ235
  source: MESH
  identifier: C531198
- word: RO4927350
  source: MESH
  identifier: C539198
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
